Chen Xin, Wen Huiying, Zhang Xinyu, Dong Changfeng, Lin Haoming, Guo Yanrong, Shan Lingbo, Yao Simin, Yang Min, Le Xiaohua, Liu Yingxia
School of Biomedical Engineering, Shenzhen University, Shenzhen, China.
National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, Shenzhen, China.
Clin Transl Gastroenterol. 2017 Apr 6;8(4):e84. doi: 10.1038/ctg.2017.11.
The accurate assessment of liver fibrosis is clinically important in patients with chronic hepatitis B (CHB). Blood tests and elastography are now widely used for the noninvasive diagnosis of liver fibrosis in CHB patients. The aim of this study was to develop a new and more accurate predictive model, which combines elastography data, serum biomarkers, and individual characteristics, to discriminate between CHB patients with and without significant liver fibrosis.
Two noninvasive methods, specifically, an ultrasound elastography technique termed acoustic radiation force impulse imaging (ARFI) and a blood test, were used to assess a cohort of 345 patients (estimation group, 218 patients; validation group, 127 patients) with CHB. Multivariate logistic regression analysis revealed that ARFI, the aspartate aminotransferase (AST) to platelet ratio, and age were significantly associated with fibrosis. Based on these results, we constructed and validated a model for the diagnosis of significant hepatic fibrosis.
The area under the receiver operating characteristic (ROC) curve was 0.921 for the estimation group and 0.929 for the validation group, significantly higher than those for ARFI (0.887, 0.893) and for the AST-to-platelet ratio index (APRI; 0.811, 0.859). Using an optimal cutoff of 3.05 in the validation group, all the indices of the proposed model, including accuracy, sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic odds ratio, were better than those for ARFI or APRI.
We developed a simple noninvasive model that used ultrasound elastography, routine serum biomarkers, and individual characteristics to accurately differentiate significant fibrosis in patients with CHB. Compared with elastography or the biomarker index alone, this model was significantly more accurate and robust.
准确评估肝纤维化对慢性乙型肝炎(CHB)患者具有重要的临床意义。血液检测和弹性成像目前广泛用于CHB患者肝纤维化的无创诊断。本研究的目的是开发一种新的、更准确的预测模型,该模型结合弹性成像数据、血清生物标志物和个体特征,以区分有和没有显著肝纤维化的CHB患者。
使用两种无创方法,具体为一种称为声辐射力脉冲成像(ARFI)的超声弹性成像技术和一项血液检测,对345例CHB患者(估计组218例;验证组127例)进行评估。多变量逻辑回归分析显示,ARFI、天冬氨酸氨基转移酶(AST)与血小板比值和年龄与纤维化显著相关。基于这些结果,我们构建并验证了一个用于诊断显著肝纤维化的模型。
估计组的受试者操作特征(ROC)曲线下面积为0.921,验证组为0.929,显著高于ARFI(0.887,0.893)和AST与血小板比值指数(APRI;0.811,0.859)。在验证组中使用最佳截断值3.05,所提出模型的所有指标,包括准确性、敏感性、特异性、阳性预测值、阴性预测值和诊断比值比,均优于ARFI或APRI。
我们开发了一种简单的无创模型,该模型使用超声弹性成像、常规血清生物标志物和个体特征来准确区分CHB患者的显著纤维化。与单独的弹性成像或生物标志物指数相比,该模型显著更准确、更可靠。